SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus

Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood. Methods: We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=462 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples. Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across all samples collected ≥28 days post symptom onset, 0/494 (0%, 95%CI 0-0.7%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA. Conclusions: vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19

Top Quark Physics

We review the prospects for studies of the top quark at the LHC.We review the prospects for studies of the top quark at the LHC. Members of the working group who have contributed to this document are: A.Ahmadov, G.Azuelos, U.Baur, A.Belyaev, E.L.Berger, W.Bernreuther, E.E.Boos, M.Bosman, A.Brandenburg, R.Brock, M.Buice, N.Cartiglia, F.Cerutti, A.Cheplakov, L.Chikovani, M.Cobal-Grassmann, G.Corcella, F.del Aguila, T.Djobava, J.Dodd, V.Drollinger, A.Dubak, S.Frixione, D.Froidevaux, B.Gonzalez Pineiro, Y.P.Gouz, D.Green, P.Grenier, S.Heinemeyer, W.Hollik, V.Ilyin, C.Kao, A.Kharchilava, R. Kinnunen, V.V.Kukhtin, S.Kunori, L.La Rotonda, A.Lagatta, M.Lefebvre, K.Maeshima, G.Mahlon, S.Mc Grath, G.Medin, R.Mehdiyev, B.Mele, Z.Metreveli, D.O'Neil, L.H.Orr, D.Pallin, S.Parke, J.Parsons, D.Popovic, L.Reina, E.Richter-Was, T.G.Rizzo, D.Salihagic, M.Sapinski, M.H.Seymour, V.Simak, L.Simic, G.Skoro, S.R.Slabospitsky, J.Smolik, L.Sonnenschein, T.Stelzer, N.Stepanov, Z.Sullivan, T.Tait, I.Vichou, R.Vidal, D.Wackeroth, G.Weiglein, S.Willenbrock, W.W

Por qué hay que abolir la terapia o el caso contra la terapia: Entrevista a Jeffrey Masson - autor del libro "Against therapy"

La terapia es una institución que ha tenido gran abundancia de celebrantes (generalmente autointeresados), pero pocos detractores serios. Ahora ha encontrado su primer abolicionista -Jeffrey Masson, quien sostiene que la terapia es un edificio constituido de tal modo, que pone en peligro a cualquier persona que entra en él-. En su nuevo libro, En Contra de la Terapia (Against Therapy), él es una empresa demoledora de una sola persona, de considerable energía e inteligencia

The first World Cell Race

In Authors: WCR participants World Wide, listed in Supplemental InformationInternational audienceMotility is a common property of animal cells. Cell motility is required for embryogenesis [1], tissue morphogenesis [2] and the immune response [3] but is also involved in disease processes, such as metastasis of cancer cells [4]. Analysis of cell migration in native tissue in vivo has yet to be fully explored, but motility can be relatively easily studied in vitro in isolated cells. Recent evidence suggests that cells plated in vitro on thin lines of adhesive proteins printed onto culture dishes can recapitulate many features of in vivo migration on collagen fibers [5,6]. However, even with controlled in vitro measurements, the characteristics of motility are diverse and are dependent on the cell type, origin and external cues. One objective of the first World Cell Race was to perform a large-scale comparison of motility across many different adherent cell types under standardized conditions. To achieve a diverse selection, we enlisted the help of many international laboratories, who submitted cells for analysis. The large-scale analysis, made feasible by this competition-oriented collaboration, demonstrated that higher cell speed correlates with the persistence of movement in the same direction irrespective of cell origin